Solid Biosciences (SLDB) closed at $6.18 on November 5, 2026, down 5.2% from the previous close, on volume of 1,376,692 shares (30-day average 1,280,826).
Data as of November 5, 2026.
5-Nov-2026
Solid Biosciences (SLDB) Gets a Buy from RBC Capital
TipRanks (Thu, 5-Nov 9:36 AM ET)
Leerink Partners Sticks to Their Buy Rating for Solid Biosciences (SLDB)
TipRanks (Thu, 5-Nov 9:29 AM ET)
Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Globe Newswire (Thu, 5-Nov 8:00 AM ET)
Solid Biosciences (SLDB) Gets a Buy from Wedbush
TipRanks (Thu, 5-Nov 7:56 AM ET)
Solid Biosciences (SLDB) Gets a Buy from Piper Sandler
TipRanks (Thu, 5-Nov 7:29 AM ET)
TipRanks (Thu, 5-Nov 7:20 AM ET)
H.C. Wainwright Sticks to Their Buy Rating for Solid Biosciences (SLDB)
TipRanks (Thu, 5-Nov 7:16 AM ET)
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Wed, 4-Nov 4:07 PM ET)
Market Chameleon (Mon, 26-Oct 4:11 AM ET)
Globe Newswire (Mon, 26-Oct 8:00 AM ET)
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Solid Biosciences trades on the NASDAQ stock market under the symbol SLDB.
As of November 5, 2026, SLDB stock price declined to $6.18 with 1,376,692 million shares trading.
SLDB has a beta of 1.67, meaning it tends to be more sensitive to market movements. SLDB has a correlation of 0.08 to the broad based SPY ETF.
SLDB has a market cap of $662.65 million. This is considered a Small Cap stock.
In the last 3 years, SLDB traded as high as $15.05 and as low as $2.00.
The top ETF exchange traded funds that SLDB belongs to (by Net Assets): VTI, IWM, XBI, VXF, IBB.
SLDB has outperformed the market in the last year with a price return of +40.3% while the SPY ETF gained +9.7%. However, in the short term, SLDB had mixed performance relative to the market. It has underperformed in the last 3 months, returning -28.3% vs -4.7% return in SPY. But in the last 2 weeks, SLDB shares have fared better than the market returning -3.6% compared to SPY -5.2%.
SLDB support price is $6.20 and resistance is $6.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLDB shares will trade within this expected range on the day.
